Proprietary lipid nanoparticle for in vivo kidney delivery.
Therapeutic payloads are directed to specific organs and cells, ensuring targeted delivery beyond the liver.
Minimize immune responses and eliminate the risk of insertional mutagenesis linked with viral vectors.
Greater scalability than viral vectors due to their simpler production processes and the ability to be synthesized in larger quantities more efficiently.
Ionizable Lipid
Cholestrol
Neutral Phospholipid
PEG Lipid
Autosomal Dominant Polycystic Kidney Disease
(due to mutations in PKD1 gene)
Autosomal Dominant Polycystic Kidney Disease
(due to mutations in PKD2 gene)
Autosomal Recessive Polycystic Kidney Disease
Tubulointerstitial Kidney Disease
